LTZ Therapeutics Series B · $38M raised · (2026)

LTZ Therapeutics has secured $38 million in Series B funding, marking a significant follow-on round to advance its immunotherapy pipeline. The company plans to utilize these funds to accelerate the development of its oncology and autoimmune disease treatments. This funding round was led by [Investor Name] and [Investor Name], with participation from [Investor Name].